Navigation Links
Clive Dix Appointed as Chairman of Crescendo Biologics
Date:1/8/2010

CAMBRIDGE, England, January 8 /PRNewswire/ -- Crescendo Biologics ("Crescendo") today announces the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent GBP4.5 million seed round fundraising.

Dr Dix has an exceptional track record established over more than 20 years in the pharmaceutical and biotechnology business. He is the Chairman of the BioIndustry Association, the trade association for innovative enterprises in the UK's bioscience sector, and was previously co-founder and Chief Executive of PowderMed Ltd, a vaccines development company acquired by Pfizer in November 2006. Prior to running PowderMed, Dr Dix was Senior Vice President, Research and Development and a Board member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. Dr Dix began his career in industry at Ciba-Geigy and then GlaxoWellcome, where he left as UK Research Director in 2001. Dr Dix is non-Executive Chairman of Modern Biosciences plc and Auralis Ltd.

Dr Dix has an in-depth understanding of all facets of the drug discovery and development process, having led projects and portfolios from conception through to Phase III in a range of therapeutic areas including cardiovascular, respiratory, inflammatory and infectious diseases.

Clive Dix said, "The antibody space remains enormously attractive for pharmaceutical and biotechnology companies. Current products have brought real benefits to patients and command huge market value, and there is a great demand for innovative antibody technologies to deliver the high value products of the future. With substantial seed funding in place, Crescendo has the opportunity to build on its world class, proprietary technology platforms and grow to become a leader in next-generation antibody therapeutics."

Handing over the Chairman's reins, lead investor Graziano Seghezzi said, "Independent leadership is what we strive for at Sofinnova when we build our companies' board of directors. I am delighted to have someone of Clive's calibre join the Company and Board."

Mike Romanos said, "Clive's experience will be invaluable as we grow our business through technology development, in-house projects and future partnership programmes. I look forward to working together."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly and predictably generate high-affinity human heavy chain antibodies that readily yield VH fragments that have no requirement for humanisation. This is combined with a powerful in vitro ribosome display technology which offers significant advantages over existing approaches in antibody optimisation. VH fragments provide great flexibility as a starting point for the development of new targeted therapeutics combining the specificity and binding affinity of antibodies with certain desirable characteristics of small molecules.

Crescendo's technologies were invented by scientists at the Babraham Institute, Cambridge (UK). The Company has raised GBP4.5 million in seed funding from leading life sciences investors, Sofinnova Partners with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating. http://www.crescendobiologics.com

    Contacts

    Mike Romanos / Amanda Bettison
    Crescendo Biologics
    Tel: +44(0)1223-497140
    Email: mromanos / abettison@crescendobiologics.com

    Chris Gardner
    Citigate Dewe Rogerson
    Tel: +44(0)207-638-9571
    Email: chris.gardner@citigatedr.co.uk

SOURCE Crescendo Biologics Ltd


'/>"/>
SOURCE Crescendo Biologics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
2. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
3. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
4. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
5. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
6. Al Novak Elected Chairman of the Board of OrbusNeich Medical
7. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
8. Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman
9. Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
10. Bracken to Become Chairman of HCAs Board of Directors Effective Dec. 15
11. Stryker Announces Change in Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
(Date:6/23/2016)... 2016  The National Pharmaceutical Council (NPC) today ... policy research organization as its newest member.  ... vice president and chief scientific officer, Mallinckrodt Pharmaceuticals, ... NPC Board of Directors. ... joined us in support of our efforts to ...
(Date:6/23/2016)... , June 23, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on treatment of primary and metastatic ... European patient education - www.againsttheodds.eu - has ... Digital Health Awards. The website ... European patients and their families who are coping with ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... 2016 , ... Today, MTI-GlobalStem, a provider of optimized transfection ... to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing System ... is a complete system for culturing and transfecting human pluripotent stem cells for ...
Breaking Medicine News(10 mins):